(Q33584641)

28 July 2017

1 reference

title

Clinical use of recombinant FVIIa (rFVIIa). (English)

1 reference

28 July 2017

Hedner U

1

1 reference

28 July 2017

Ingerslev J

series ordinal

2

1 reference

28 July 2017

publication date

1 June 1998

1 reference

28 July 2017

1 reference

28 July 2017

volume

19

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

163-176

1 reference

Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Platelet activity of high-dose factor VIIa is independent of tissue factor

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Accumulation of the recombinant factor VIIa in rat bone: importance of the Gla-domain and relevance to factor IX, another vitamin K-dependent clotting factor

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Recombinant factor VIIa in an infant with haemophilia A and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

rVIIa therapy to secure haemostasis during central line insertion in children with high-responding FVIII inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Experience with recombinant factor VIIA in an infant hemophiliac with inhibitors to FVIII:C undergoing emergency central line placement. A case report.

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Control of haemostasis with recombinant factor VIIa in patient with inhibitor to factor VIII

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Recombinant factor VIIa in the management of a pseudotumour in acquired haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Use of recombinant factor VIIa in surgery in factor-VII-deficient patients

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2898%2900026-5

7 January 2021

10.1016/S0955-3886(98)00026-5

Identifiers

DOI

1 reference

28 July 2017

1 reference